<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389428</url>
  </required_header>
  <id_info>
    <org_study_id>CLTR0305-101</org_study_id>
    <nct_id>NCT00389428</nct_id>
  </id_info>
  <brief_title>Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.</brief_title>
  <official_title>Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the recommended dose of CPX-351 for use&#xD;
      in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the&#xD;
      safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of&#xD;
      antitumor activity will also be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs&#xD;
      cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar&#xD;
      ratio. The development of CPX-351 (cytarabine:daunorubicin) Liposome Injection was based on&#xD;
      1) defining a synergistic ratio of the two active moieties, cytarabine and daunorubicin,&#xD;
      using cell-based screening assays and 2) designing a liposomal drug carrier to maintain this&#xD;
      ratio after intravenous administration. CPX-351 was found to be more active in in vivo models&#xD;
      of cancer than combinations of conventional cytarabine and daunorubicin. Both cytarabine and&#xD;
      daunorubicin are active chemotherapeutic agents, each approved for clinical use in the United&#xD;
      States for the treatment of hematological neoplasms.&#xD;
&#xD;
      CPX-351 is being developed with the hypothesis that it is superior to the currently used&#xD;
      regimen of cytarabine and daunorubicin in the treatment of acute leukemia. This phase I study&#xD;
      will determine the dose to carry forward into phase II trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) for use in phase 2</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and dose-limiting toxicities (DLT) of CPX-351.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic parameters of CPX-351 administered in this schedule.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess preliminary efficacy information of CPX-351 administered in this schedule in patients with advanced leukemias.</measure>
  </secondary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351 (Cytarabine:Daunorubicin) Liposome Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and voluntarily sign an informed consent form&#xD;
&#xD;
          -  Age &gt; 18 years at the time of signing the informed consent form&#xD;
&#xD;
          -  Pathological confirmation of leukemia or myelodysplastic syndrome.&#xD;
&#xD;
          -  AML according to WHO criteria; except for core-binding factor AMLs (t(8;21), inv(16)&#xD;
             or t(16;16)) and APL&#xD;
&#xD;
          -  ALL&#xD;
&#xD;
          -  MDS&#xD;
&#xD;
          -  Patients with AML include the following:&#xD;
&#xD;
          -  Patients in 2nd or greater relapse&#xD;
&#xD;
          -  Patients in first relapse with initial CR duration lasting &lt;6 months&#xD;
&#xD;
          -  Patients in first relapse refractory to induction therapy&#xD;
&#xD;
          -  Patients with primary refractory AML&#xD;
&#xD;
          -  Patients with ALL include the following&#xD;
&#xD;
          -  Patients with T-cell ALL refractory or in relapse following nelarabine&#xD;
&#xD;
          -  Patients with other ALL that is refractory or in relapse.&#xD;
&#xD;
          -  Patients with MDS include the following:&#xD;
&#xD;
          -  The subset of RAEB-2 patients with &gt;10% blasts with at least 1 prior therapy that&#xD;
             includes a hypomethylating agent.&#xD;
&#xD;
          -  Previously untreated chemotherapy induced AML&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1 or 2&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Laboratory values fulfilling the following:&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Serum total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Serum alanine aminotransferase or aspartate aminotransferase &lt; 150 IU/liter Note: If&#xD;
             elevated liver enzymes are related to disease; contact medical monitor to discuss.&#xD;
&#xD;
          -  Cardiac ejection fraction &gt; 50% by MUGA scan or echocardiography&#xD;
&#xD;
          -  All men and women must agree to practice effective contraception during the study&#xD;
             period if not otherwise documented to be infertile.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality or psychiatric illness that&#xD;
             would prevent the patient from signing the informed consent form&#xD;
&#xD;
          -  Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks&#xD;
             prior to study entry; in the event of rapidly proliferative disease, however, the use&#xD;
             of hydroxyurea is permitted up to 24 hours before study entry&#xD;
&#xD;
          -  Clinical evidence of active CNS leukemic involvement&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Clinically significant cardiac disease (New York Heart Association Class III or IV)&#xD;
&#xD;
          -  Severe debilitating pulmonary disease&#xD;
&#xD;
          -  Active and uncontrolled infection. Patients with an infection under active treatment&#xD;
             with antibiotics and whose infection is controlled may be entered into the study&#xD;
&#xD;
          -  Current evidence of invasive fungal infection (blood or tissue culture); HIV or&#xD;
             hepatitis C infection&#xD;
&#xD;
          -  Hypersensitivity to cytarabine, daunorubicin or liposomal products&#xD;
&#xD;
          -  History of Wilson's disease or other copper-related disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Louie, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Jazz Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Kolitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York School of Medicine at North Shore University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffit Cancer Center &amp; Research Institute at the University of S. Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <last_update_submitted>May 16, 2012</last_update_submitted>
  <last_update_submitted_qc>May 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic malignancies</keyword>
  <keyword>Malignancies, hematologic</keyword>
  <keyword>Hematopoietic malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

